DUBLIN--(BUSINESS WIRE)--The "North America Digital Genome Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
North America market for digital genome is expected to rise with a CAGR of 9.75%
The United States dominates North America's genome editing market. The high rate of adoption of advanced technology, the presence of big industry names, high funds for genomic research are all factors attributable to the major share of the country in this market.
Further, extensive research activities in genomics, gene editing, cell line culture, and modification are being conducted, which is boosting the market growth in the US. Several globally-renowned manufacturers of DNA sequencing technologies, equipment, and platforms are active in the US.
For instance, several prominent names in the DNA sequencing industry, such as Thermo Fisher Scientific, Illumina, and others have their corporate presence in the nation, and the enhanced adoption of DNA sequencing has led to a rise in the creation of genomic databases like Ensembl Human Genome Server, UCSC Human Genome Browser Gateway, and others. These factors are projected to drive the digital genome market in the US.
In addition, factors like growing awareness of DNA sequencing, and its applications in different fields, including personalized medicine, clinical diseases, agri-genomics, and others, are contributing to market progress.
COMPETITIVE OUTLOOK
Some of the companies present in this market include Oxford Nanopore Technologies Ltd, Inscripta, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company (BD), Pacific Bioscience, and Abbott Laboratories.
Key Topics Covered:
1. North America Digital Genome Market - Summary
2. Industry Outlook
2.1. Porter's Five Forces Model
2.2. Impact of Covid-19 on Digital Genome Market
2.3. Market Attractiveness Index
2.4. Vendor Landscape
2.5. Key Insights
2.6. Key Drivers
2.6.1. Proliferating Burden of Chronic Diseases
2.6.2. Continuous Funding by the Manufacturers and Government in the Field of Genomics
2.7. Key Restraints
2.7.1. Security Risks Associated With Digital Genome
2.7.2. Lack of Skilled Professionals in the Field of Genome Technology
2.8. Key Opportunities
2.8.1. Technological Advancements
2.8.2. Prevailing Awareness in the Developing Economies Regarding Dna Sequencing Technologies
3. Digital Genome Market Outlook - by Product
3.1. Sequencing and Analyzer Instruments
3.2. Dna/Rna Analysis
3.3. Sequencing and Analysis Software
3.4. Sequencing Chips
3.5. Sample Prep Instruments
4. Digital Genome Market Outlook - by Application
4.1. Diagnostics
4.2. Drug Discovery
4.3. Academic Research
4.4. Personalized Medicine
4.5. Agricultural
4.6. Other Applications
5. Digital Genome Market Outlook - by End-User
5.1. Diagnostics and Forensic Labs
5.2. Academic Research Institutes
5.3. Hospitals
5.4. Other End-Users
6. Digital Genome Market - North America
6.1. Country Analysis
6.1.1. The United States
6.1.2. Canada
7. Company Profile
7.1. Qiagen Nv
7.2. Oxford Nanopore Technologies Ltd
7.3. Becton, Dickinson, and Company (Bd)
7.4. Illumina Inc
7.5. Thermo Fisher Scientific Inc
7.6. Pacific Bioscience
7.7. Bio-Rad Laboratories Inc
7.8. F. Hoffmann-La Roche
7.9. Perkinelmer Inc
7.10. Regeneron Pharmaceuticals
7.11. Biomerieux Sa
7.12. Abbott Laboratories
7.13. Agilent Technologies Inc.
7.14. Inscripta
8. Research Methodology & Scope
Companies Mentioned
- Qiagen Nv
- Oxford Nanopore Technologies Ltd
- Becton, Dickinson, and Company (Bd)
- Illumina Inc
- Thermo Fisher Scientific Inc
- Pacific Bioscience
- Bio-Rad Laboratories Inc
- F. Hoffmann-La Roche
- Perkinelmer Inc
- Regeneron Pharmaceuticals
- Biomerieux Sa
- Abbott Laboratories
- Agilent Technologies Inc.
- Inscripta
For more information about this report visit https://www.researchandmarkets.com/r/ib20qm
